Morpholino

MO1-ptger2a

ID

ZDB-MRPHLNO-060302-1

Name

MO1-ptger2a

Previous Names

ep2-MO1 (1)
MO1-ptger2l (1)

Target

ptger2a (1)

Sequence

5' - GATGTTGGCATGTTTGAGAGCATGC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

translation blocker targeted to 5'-UTR

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-ptger2a

Expressed Gene	Anatomy	Figures
slc12a1	pronephric distal early tubule	Fig. 4 from Poureetezadi et al., 2016
slc12a3	pronephric distal late tubule	Fig. 4 from Poureetezadi et al., 2016

Phenotype

Phenotype resulting from MO1-ptger2a

Phenotype	Fish	Figures
pronephric distal early tubule slc12a1 expression increased distribution, abnormal	TU + MO1-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule increased size, abnormal	TU + MO1-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal	TU + MO1-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule decreased size, abnormal	TU + MO1-ptger2a	Fig. 4 from Poureetezadi et al., 2016

Phenotype of all Fish created by or utilizing MO1-ptger2a

Phenotype	Fish	Conditions	Figures
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal	TU + MO1-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule size, ameliorated	TU + MO1-ptger2a	chemical treatment by environment: 16,16-dimethylprostaglandin E2	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule decreased size, abnormal	TU + MO1-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule slc12a1 expression spatial pattern, ameliorated	TU + MO1-ptger2a	chemical treatment by environment: 16,16-dimethylprostaglandin E2	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule slc12a1 expression increased distribution, abnormal	TU + MO1-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule increased size, abnormal	TU + MO1-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule size, ameliorated	TU + MO1-ptger2a	chemical treatment by environment: 16,16-dimethylprostaglandin E2	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule slc12a3 expression spatial pattern, ameliorated	TU + MO1-ptger2a	chemical treatment by environment: 16,16-dimethylprostaglandin E2	Fig. 4 from Poureetezadi et al., 2016
hematopoietic stem cell decreased amount, abnormal	WT + MO1-ptger2a + MO2-ptger2a	standard conditions	Fig. S1 from North et al., 2007
exocrine pancreas size, ameliorated	WT + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal	WT + MO1-ptger2a + MO2-ptger2a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO2-ptger2a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression amount, ameliorated	WT + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO2-ptger2a	control	Fig. 1 from Nissim et al., 2014
liver EGFP expression decreased distribution, abnormal	as3Tg + MO1-ptger2a + MO2-ptger2a	control	Fig. 1 from Nissim et al., 2014
liver size, ameliorated	as3Tg + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver EGFP expression amount, ameliorated	as3Tg + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal	TU + MO1-ptger2a + MO1-ptgs1	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule decreased size, abnormal	TU + MO1-ptger2a + MO1-ptgs1	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule slc12a1 expression increased distribution, abnormal	TU + MO1-ptger2a + MO1-ptgs1	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule increased size, abnormal	TU + MO1-ptger2a + MO1-ptgs1	standard conditions	Fig. 4 from Poureetezadi et al., 2016
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression amount, ameliorated	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 1 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas size, ameliorated	zf578Tg + MO1-ptger2a + MO1-ptgs2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptger2a + MO1-ptgs2a	control	Fig. 2 from Nissim et al., 2014

Citations